"Our long-term aim is also to help the company get into a position where it can attract the consistent funding it will need to successfully complete a Phase III clinical study and beyond. If the company is going to move into a sustainable position to attract a broader range of investors that, in turn, will give it a runway to complete its clinical trials, it needs to put these allegations to rest once and for all.... -- Neil Woodford, a month ago
Then yesterday, after previously agreeing to NWBO's plans to hire Mr. Price, he said this:
Woodford Investment Management replied that they view the level of due diligence as adequate and the investment [Northwest Biotherapeutics] remains in the portfolio. -- January 7, 2016
Respect Risk. Conduct Your Own Due Diligence. Manage your assets wisely. Diversify.